Stock Track | GeneDx Holdings Soars 5.31% Pre-Market on Strong Q1 Results and Raised Guidance

Stock Track

May 01, 2025

Shares of GeneDx Holdings (WGS) surged 5.31% in pre-market trading following the company's release of impressive first-quarter 2025 results and an upward revision of its full-year guidance. The genetic testing company reported robust growth in its core exome and genome business, along with strategic expansions that have bolstered investor confidence.

GeneDx announced Q1 2025 revenues of $87.1 million, with exome and genome revenues growing an impressive 62% year-over-year to $71.4 million. This strong performance led the company to raise its full-year 2025 revenue guidance to $360 million to $375 million. CEO Katherine Stueland highlighted the company's third consecutive quarter of profitability and emphasized their strengthening industry-leading position in diagnosing genetic diseases.

Adding to the positive sentiment, GeneDx revealed several strategic initiatives driving future growth. These include the launch of an ultraRapid Genome Sequencing product with a 48-hour turnaround time, expansion into new clinical indications such as immune deficiency disorders, and plans to acquire Fabric Genomics to enhance AI-powered genomic interpretation capabilities. With these developments and the company's focus on integrating exome and genome testing more proactively as the standard of care, investors appear optimistic about GeneDx's growth trajectory in the evolving field of genetic diagnostics.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1118150199"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1118150199\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1118150199?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-01 21:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118150199","market":"sg","top_or_hot":-1,"title":"Stock Track | GeneDx Holdings Soars 5.31% Pre-Market on Strong Q1 Results and Raised Guidance","media":"Stock Track","content":"<p>Shares of GeneDx Holdings (WGS) surged 5.31% in pre-market trading following the company's release of impressive first-quarter 2025 results and an upward revision of its full-year guidance. The genetic testing company reported robust growth in its core exome and genome business, along with strategic expansions that have bolstered investor confidence.</p>\n\n<p>GeneDx announced Q1 2025 revenues of $87.1 million, with exome and genome revenues growing an impressive 62% year-over-year to $71.4 million. This strong performance led the company to raise its full-year 2025 revenue guidance to $360 million to $375 million. CEO Katherine Stueland highlighted the company's third consecutive quarter of profitability and emphasized their strengthening industry-leading position in diagnosing genetic diseases.</p>\n\n<p>Adding to the positive sentiment, GeneDx revealed several strategic initiatives driving future growth. These include the launch of an ultraRapid Genome Sequencing product with a 48-hour turnaround time, expansion into new clinical indications such as immune deficiency disorders, and plans to acquire Fabric Genomics to enhance AI-powered genomic interpretation capabilities. With these developments and the company's focus on integrating exome and genome testing more proactively as the standard of care, investors appear optimistic about GeneDx's growth trajectory in the evolving field of genetic diagnostics.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GeneDx Holdings Soars 5.31% Pre-Market on Strong Q1 Results and Raised Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GeneDx Holdings Soars 5.31% Pre-Market on Strong Q1 Results and Raised Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-05-01 21:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of GeneDx Holdings (WGS) surged 5.31% in pre-market trading following the company's release of impressive first-quarter 2025 results and an upward revision of its full-year guidance. The genetic testing company reported robust growth in its core exome and genome business, along with strategic expansions that have bolstered investor confidence.</p>\n\n<p>GeneDx announced Q1 2025 revenues of $87.1 million, with exome and genome revenues growing an impressive 62% year-over-year to $71.4 million. This strong performance led the company to raise its full-year 2025 revenue guidance to $360 million to $375 million. CEO Katherine Stueland highlighted the company's third consecutive quarter of profitability and emphasized their strengthening industry-leading position in diagnosing genetic diseases.</p>\n\n<p>Adding to the positive sentiment, GeneDx revealed several strategic initiatives driving future growth. These include the launch of an ultraRapid Genome Sequencing product with a 48-hour turnaround time, expansion into new clinical indications such as immune deficiency disorders, and plans to acquire Fabric Genomics to enhance AI-powered genomic interpretation capabilities. With these developments and the company's focus on integrating exome and genome testing more proactively as the standard of care, investors appear optimistic about GeneDx's growth trajectory in the evolving field of genetic diagnostics.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"WGS","symbol_name":"GeneDx Holdings","start_time":0,"source_url":"","article_id":"1118150199","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118150199","pubTimestamp":1746105388,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of GeneDx Holdings  surged 5.31% in pre-market trading following the company's release of impressive first-quarter 2025 results and an upward revision of its full-year guidance. The genetic testing company reported robust growth in its core exome and genome business, along with strategic expansions that have bolstered investor confidence.GeneDx announced Q1 2025 revenues of $87.1 million, with exome and genome revenues growing an impressive 62% year-over-year to $71.4 million. This strong","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"WGS":"GeneDx Holdings"},"translate_title":"股票赛道GeneDx Holdings因强劲的第一季度业绩和上调指引而盘前飙升5.31%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WGS":1},"content_text":"Shares of GeneDx Holdings (WGS) surged 5.31% in pre-market trading following the company's release of impressive first-quarter 2025 results and an upward revision of its full-year guidance. The genetic testing company reported robust growth in its core exome and genome business, along with strategic expansions that have bolstered investor confidence.\nGeneDx announced Q1 2025 revenues of $87.1 million, with exome and genome revenues growing an impressive 62% year-over-year to $71.4 million. This strong performance led the company to raise its full-year 2025 revenue guidance to $360 million to $375 million. CEO Katherine Stueland highlighted the company's third consecutive quarter of profitability and emphasized their strengthening industry-leading position in diagnosing genetic diseases.\nAdding to the positive sentiment, GeneDx revealed several strategic initiatives driving future growth. These include the launch of an ultraRapid Genome Sequencing product with a 48-hour turnaround time, expansion into new clinical indications such as immune deficiency disorders, and plans to acquire Fabric Genomics to enhance AI-powered genomic interpretation capabilities. With these developments and the company's focus on integrating exome and genome testing more proactively as the standard of care, investors appear optimistic about GeneDx's growth trajectory in the evolving field of genetic diagnostics.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}